publication date: Mar. 1, 2019

In Brief

NCORP networks to take part in NCI’s Moonshot Tissue Procurement Protocol

Twelve NCI Community Oncology Research Program networks were awarded the opportunity to participate in NCI Protocol 10231: The NCORP Tissue Procurement Protocol, an NCI Cancer Moonshot Study.

The primary endpoint of the study is to obtain tumor tissue and blood specimens for bio-banking and to store tissues, blood, and nucleic acids for future research, including the study of matched pre and post-treatment tumor biopsies to elucidate mechanisms of resistance. 

Cases will be grouped according to histology and/or treatment. The secondary endpoint is to store tumor tissues in the Bio-pathology Center at Nationwide Children’s Hospital, perform genomic studies, including a pan-cancer gene panel, and contribute molecular data to the Genomic Data Commons.

The study is led by Fernanda Arnaldez, a physician in the Investigational Therapeutics Section of NCI’s Cancer Therapy Evaluation Program. She is also the scientific officer for the Experimental Therapeutics Clinical Trials Network and coordinator for the Early Drug Development Opportunity Program.

The participating NCORPs are:

Aurora NCORP

Columbia University Minority Underserved NCORP

Georgia NCORP – Lewis Cancer Center

Gulf South Minority Underserved NCORP – New Orleans Cancer Center

Hawaii Minority Underserved NCORP

Heartland Cancer Research NCORP (St. Louis)

Iowa-Wide Oncology Research Coalition (I-WORC)

Michigan Cancer Research Consortium NCORP

Metro Minnesota Community Oncology Research Consortium

Montefiore Minority Underserved NCORP

Puerto Rico Minority Underserved NCORP – Doctors Cancer Center

Southeast Clinical Oncology Research (SCOR) Consortium NCORP

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.